NCCN to Host Policy Summit Addressing the Impact of Health Care Reform on Academic Oncology Practice
On July 10, 2014, NCCN will host the NCCN Policy Summit: The Impact of Health Care Reform on Academic Oncology Practice, at The Westin Arlington Gateway in Arlington, Virginia, as part of the NCCN Oncology Policy Program.
30-Jun-2014 2:00 PM EDT
NCCN has launched its Reimbursement Resource App, which offers patients, providers, case managers, and payers access to payment assistance and reimbursement programs for multiple cancer types; the app is available free of charge for Apple and...
18-Jun-2014 12:05 PM EDT
Six Organizations Receive Grants from NCCN and Pfizer for Health Care Quality Improvement Programs in Rare Cancers
The NCCN Oncology Research Program (ORP) and Pfizer Independent Grants for Learning & Change have awarded six independent grants to implement quality improvement and health care professional education in renal cell carcinoma and hematologic...
5-Jun-2014 11:10 AM EDT
The NCCN Foundation® has awarded the fourth series of Young Investigator Awards to five young investigators from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing...
29-May-2014 10:00 AM EDT
NCCN Receives $2 Million in Research Funding from Boehringer Ingelheim to Study Volasertib* in Hematologic Malignancies
The NCCN Oncology Research Program (ORP) received a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to facilitate studies of volasertib in hematologic malignancies.
22-May-2014 10:15 AM EDT
New NCCN Guidelines for Patients®: Breast Cancer Stages 0 – IV now available free-of-charge at NCCN.org/patients; NCCN Guidelines for Patients® are educational resources that offer patient-friendly treatment information.
5-May-2014 10:30 AM EDT
The third annual NCCN State Oncology Society Forum, held at the NCCN 19th Annual Conference, examining the evaluation of quality in oncology, the utilization of clinical guidelines and pathways, and the consequences with the Sunshine Act.
2-Apr-2014 9:15 AM EDT
NCCN Receives $2.2 Million in Research Funding From Astellas and Medivation to Study Enzalutamide in Solid Tumors
The NCCN Oncology Research Program (ORP) received a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to facilitate studies of enzalutamide in bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.
31-Mar-2014 1:00 PM EDT